FDA Issues 4 Observations To Biocon's Andhra Pradesh Facility
Biocon receives four US FDA observations at Visakhapatnam API facility, plans prompt resolution.
Biocon, a biotechnology company, reported that the US FDA has issued four observations following its inspection of Biocon's manufacturing plant in Andhra Pradesh. The inspection, focused on Biocon's API facility (Site 5) in Visakhapatnam, Andhra Pradesh, concluded on June 21, 2024, according to a regulatory filing by the company. It also added that "Four observations were cited at the end of the inspection, which we will be addressing within the stipulated time.”
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Novo Nordisk Firma un Accordo da $2.6B con Hengrui per GLP-1 Orale
Discussion